Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

40.04
+0.37000.93%
Post-market: 40.840.8000+2.00%19:59 EDT
Volume:786.77K
Turnover:31.56M
Market Cap:3.85B
PE:-20.47
High:40.46
Open:39.73
Low:39.12
Close:39.67
52wk High:40.58
52wk Low:23.23
Shares:96.27M
Float Shares:94.37M
Volume Ratio:0.88
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.22
PE(LYR):-31.16

Loading ...

IDEAYA Biosciences and Servier Announce Positive Topline Results From Phase 2/3 Registrational Trial (Optimum-02) of Darovasertib in Combination With Crizotinib in First-Line Hla-a*02:01-Negative Metastatic Uveal Melanoma

THOMSON REUTERS
·
Apr 13

Why IDEAYA Biosciences Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

Benzinga_recent_news
·
Apr 13

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA) and Certara (CERT)

TIPRANKS
·
Apr 13

Ideaya Biosciences Shares Gain Ahead of Trial Results

Dow Jones
·
Apr 11

BRIEF-Ideaya Biosciences To Announce Topline Results From Phase 2/3 Optimum-02 Trial In Metastatic Uveal Melanoma On Monday, April 13, 2026

Reuters
·
Apr 11

IDEAYA to report topline OptimUM-02 darovasertib-crizotinib trial results April 13

Reuters
·
Apr 11

IDEAYA Biosciences to Announce Topline Results From Phase 2/3 Optimum-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

THOMSON REUTERS
·
Apr 11

BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman

Reuters
·
Apr 10

Ideaya Biosciences Inc - Enters Clinical Collaboration Agreement With Astrazeneca On April 8, 2026 - SEC Filing

Reuters
·
Apr 09

IDEAYA, AstraZeneca partner to test IDE849 with Imfinzi in small cell lung cancer

Reuters
·
Apr 09

IDEAYA Biosciences Inc - Co to Sponsor Study; AstraZeneca to Supply Imfinzi - SEC Filing

THOMSON REUTERS
·
Apr 09

IDEAYA Biosciences Inc - Agreement to Evaluate Ide849 With Imfinzi in Extensive-Stage Small Cell Lung Cancer - SEC Filing

THOMSON REUTERS
·
Apr 09

IDEAYA Biosciences Inc - Advancing Global Phase 1 Trial for Ide849 in Dll3 Upregulated Solid Tumors - SEC Filing

THOMSON REUTERS
·
Apr 09

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, Denali

Reuters
·
Apr 07

BUZZ-U.S. STOCKS ON THE MOVE-Tyson Foods, Atmus Filtration, Avis Budget

Reuters
·
Apr 06

BUZZ-U.S. STOCKS ON THE MOVE-Legence, Valero Energy, Stereotaxis

Reuters
·
Apr 06

BUZZ-U.S. STOCKS ON THE MOVE-Soleno Therapeutics, Ideaya Biosciences, Profusa

Reuters
·
Apr 06

Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (PTHS), IDEAYA Biosciences (IDYA) and Viridian Therapeutics (VRDN)

TIPRANKS
·
Apr 06

BUZZ-IDEAYA Biosciences rises as early-stage cancer trial starts

Reuters
·
Apr 06

IDEAYA enrolls first patient in Phase 1 trial of KAT6/7 inhibitor IDE574

Reuters
·
Apr 06